Comparative Pharmacology
Head-to-head clinical analysis: METRO I V versus METROGEL VAGINAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRO I V versus METROGEL VAGINAL.
METRO I.V. vs METROGEL-VAGINAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.
Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.
15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.
One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.
None Documented
None Documented
8 hours (range 6-10 hours) in adults; prolonged to 12-24 hours in hepatic impairment.
Terminal elimination half-life: 6-8 hours (prolonged in hepatic impairment; half-life may exceed 20 hours in severe hepatic disease)
Renal: 60-80% unchanged; fecal: 6-15% (includes metabolites); biliary: minor contribution.
Renal: 60-80% unchanged; fecal/biliary: 6-15%
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)